References
1. Cesaro S, Tridello G, Castagnola E, et al. Retrospective
study on the incidence and outcome of proven and probable invasive
fungal infections in high-risk pediatric onco-hematological patients.Eur J Haematol. 2017;99(3):240-248. doi: 10.1111/ejh.12910
2. Kobayashi R, Hori D, Sano H, Suzuki D, Kishimoto K,
Kobayashi K. Risk Factors for Invasive Fungal Infection in Children and
Adolescents With Hematologic and Malignant Diseases: A 10-year Analysis
in a Single Institute in Japan. Pediatr Infect Dis J.2018;37(12):1282-1285.
3. Puia-Dumitrescu M, Smith PB. Antifungal Drugs in Newborns
and Children. Pediatr Clin North Am. 2017;64(6):1389-1402. doi:
10.1016/j.pcl.2017.08.013.
4. Ramos-Martín V, O’Connor O, Hope W. Clinical pharmacology of
antifungal agents in pediatrics: children are not small adults.Curr Opin Pharmacol. 2015;24:128-34. doi:
10.1016/j.coph.2015.08.009.
5. Pagano L, Caira M, Valentini CG, Posteraro B, Fianchi L.
Current therapeutic approaches to fungal infections in immunocompromised
hematological patients. Blood Rev. 2010;24(2):51-61. doi:
10.1016/j.blre.2009.11.003.
6. Candoni A, Caira M, Cesaro S, et al; SEIFEM GROUP
(Sorveglianza Epidemiologica Infezioni Fungine nelle Emopatie Maligne).
Multicentre surveillance study on feasibility, safety and efficacy of
antifungal combination therapy for proven or probable invasive fungal
diseases in haematological patients: the SEIFEM real-life combo study.Mycoses. 2014;57(6):342-50. doi: 10.1111/myc.12161.
7. Day JN, Chau IT, Lalloo DG. Combination antifungal therapy
for Cryptococcal Meningitis. N Engl J Med. 2013;368:2522–3.
8. Mihu CN, Kassis C, Ramos ER, Jiang Y, Hachem RY, Raad II.
Does combination of lipid formulation of amphotericin B and
echinocandins improve outcome of invasive aspergillosis in hematological
malignancy patients? Cancer. 2010;116(22):5290-6. doi:
10.1002/cncr.25312.
9. MacCallum DM, Whyte JA, Odds FC. Efficacy of caspofungin and
voriconazole combinations in experimental aspergillosis.Antimicrob Agents Chemother. 2005;49:3697–701.
10. Ibrahim AS, Gebremariam T, Fu Y, et al. Combination
echinocandin polyene treatment of murine mucormycosis. Antimicrob
Agents Chemother. 2008;52:1556–8.
11. Kirkpatrick WR, Coco BJ, Patterson TF. Sequential or
combination antifungal therapy with voriconazole and liposomal
amphotericin B in a guinea pig model of invasive aspergillosis.Antimicrob Agents Chemother. 2006;50:1567–9.
12.Cesaro
S,
Giacchino
M,
Locatelli
F,
Spiller
M,
Buldini
B,
Castellini
C, et al. Safety and efficacy of a caspofungin-based combination
therapy for treatment of proven or probable aspergillosis in pediatric
hematological patients. BMC Infect Dis. 2007;7:28.
13.Raad
II,
Zakhem
AE,
Helou
GE,
Jiang
Y,
Kontoyiannis
DP,
Hachem
R. Clinical experience of the use of voriconazole, caspofungin or the
combination in primary and salvage therapy of invasive aspergillosis in
haematological malignancies. Int J Antimicrob Agents.2015;45(3):283-8. doi: 10.1016/j.ijantimicag.2014.08.012.
14.Wattier
RL,
Dvorak
CC,
Hoffman
JA,Brozovich
AA,
Bin-Hussain
I,
Groll
AH, et al. A Prospective, International Cohort Study of Invasive Mold
Infections in Children. J Pediatric Infect Dis Soc.2015;4(4):313-22. doi: 10.1093/jpids/piu074
15.Marr
KA,
Schlamm
HT,
Herbrecht
R,
Rottinghaus
ST,
Bow
EJ,
Cornely
OA, et al. Combination antifungal therapy for invasive aspergillosis: a
randomized trial. Ann Inern Med. 2015;162(2):81-9. doi:
10.7326/M13-2508.
16. Segal BH, Herbrecht R, Stevens DA, et al. Defining
responses to therapy and study outcomes in clinical trials of invasive
fungal diseases: Mycoses Study Group and European Organization for
Research and Treatment of Cancer consensus criteria. Clin Infect
Dis. 2008;47:674-83.
17. Groll AH, Castagnola E, Cesaro S, et al. Fourth European
Conference on Infections in Leukaemia (ECIL-4): guidelines for
diagnosis, prevention, and treatment of invasive fungal diseases in
paediatric patients with cancer or allogeneic haemopoietic stem-cell
transplantation. Lancet Oncol. 2014;15:e327-40.
18.Patterson
TF,
Thompson
GR 3rd,
Denning
DW,
Fishman
JA,
Hadley
S,
Herbrecht
R, et al. Practice Guidelines for the Diagnosis and Management of
Aspergillosis: 2016 Update by the Infectious Diseases Society of
America. Clin Infect Dis. 2016;63(4):e1-e60. doi:
10.1093/cid/ciw326.
19.
Lee
KH, Lim
YT, Hah
JO, Kim
YK, Lee
CH, Lee
JM. Voriconazole plus caspofungin for treatment of invasive fungal
infection in children with acute leukemia.Blood
Res. 2017;52(3):167-173.
20. Kurosawa M, Yonezumi M, Hashino S, et al. Epidemiology and
treatment outcome of invasive fungal infections in patients with
hematological malignancies. Int J Hematol. 2012;96:748-57.
21.
Georgiadou
SP, Pongas
G, Fitzgerald
NE, Lewis
RE, Rytting
M, Marom
EM, Kontoyiannis
DP. Invasive Mold Infections in Pediatric Cancer Patients Reflect
Heterogeneity in Etiology, Presentation, and Outcome: A 10-Year,
Single-Institution, Retrospective Study.J Pediatric Infect
Dis Soc. 2012 Jun;1(2):125-35.
22.
Raad
II, Zakhem
AE, Helou
GE, Jiang
Y, Kontoyiannis
DP, Hachem
R. Clinical experience of the use of voriconazole, caspofungin or the
combination in primary and salvage therapy of invasive aspergillosis
in haematological malignancies.Int
J Antimicrob Agents. 2015;45(3):283-8.
23. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi
MG, Patterson TF. In vitro interaction of caspofungin acetate with
voriconazole against clinical isolates of Aspergillus spp.Antimicrob Agents Chemother. 2002;46:3039–41.
24. Petraitis V, Petraitiene R, Sarafandi AA, Kelaher AM, Lyman
CA, Casler HE, et al. Combination therapy in treatment of experimental
pulmonary aspergillosis: synergistic interaction between an antifungal
triazole and an echinocandin. J Infect Dis. 2003;187:1834–43.
25. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination
antifungal therapy for invasive aspergillosis. Clin Infect Dis.2004;39:797–802.
26. Groll AH, Silling G, Young C, Schwerdtfeger R, Ostermann H,
Heinz WJ, et al.
Randomized comparison of safety and pharmacokinetics of caspofungin,
liposomal amphotericin B, and the combination of both in allogeneic
hematopoietic stem cell recipients. Antimicrob Agents Chemother.2010;54(10):4143-9. doi: 10.1128/AAC.00425-10.
Table 1. Demographic and clinical characteristics of the
patients, and data for IFI episodes.